Key Takeaways:
Fractyl Health Inc.'s Revita duodenal mucosal resurfacing system helped patients retain 84% of GLP-1-induced weight loss one year after stopping tirzepatide, compared with 46% for sham patients, according to one-year data from the REMAIN-1 Midpoint Cohort released Wednesday. The clinical-stage company's shares surged as much as 20.1% to 96 cents in afternoon trading on the Nasdaq.
"The success of GLP-1 medicines has created a new unsolved problem: what happens when patients stop," Harith Rajagopalan, co-founder and chief executive officer of Fractyl Health, said in a statement. "Today's results are the first randomized, sham-controlled evidence that a single Revita procedure can keep most of the weight off for a full year after GLP-1 is stopped."
Revita is a single-use endoscopic catheter that delivers hydrothermal ablation to the duodenal mucosa, the first 25 centimeters of the small intestine beyond the stomach. The procedure targets damaged tissue to enable regeneration of healthier mucosa that could restore normal metabolic regulation. The system received FDA breakthrough device designation in 2021.
In the full modified intention-to-treat population of 45 participants who had lost at least 15% of body weight on tirzepatide before discontinuing, Revita reduced weight regain by approximately 40% versus sham — a least-squares mean regain of 7.8% of body weight compared with 13.0%. Among patients who received complete duodenal ablation exceeding 14 centimeters, Revita maintained approximately 81% of GLP-1-induced weight loss at one year versus 48% for sham, reflecting a reduction in weight regain of more than 60%.
The optimized subgroup — patients with complete ablation who had lost at least 17.5% during the GLP-1 run-in — showed the strongest results: 84% weight loss maintenance versus 46% for sham, with least-squares mean weight regain of 4.1% versus 13.5%. Fractyl said this suggests patients at greatest risk of regaining weight after stopping GLP-1 therapy may derive the most benefit.
The weight-maintenance responder rate — measuring the proportion of patients maintaining at least 5% total body weight loss relative to their pre-tirzepatide weight at one year — reached 73% in the mITT population and rose to 91% in those with complete duodenal ablation. No device- or procedure-related serious adverse events occurred. Overall treatment-emergent adverse event rates were comparable between arms at 24% for Revita versus 25% for sham, limited to mild peri-procedural events such as abdominal discomfort, sore throat, nausea and dry mouth that resolved within two days. One new diagnosis of type 2 diabetes occurred in the sham arm versus none with Revita.
Rajagopalan described Revita as "like LASIK for obesity" on an investor call, positioning the single outpatient procedure as an alternative to chronic medication for weight maintenance. The company's next milestones include topline six-month randomized data from the REMAIN-1 Pivotal Cohort expected in early Q4 2026, followed by a potential FDA De Novo marketing application submission in late Q4 2026.
The results position Revita as a potential first-in-class procedural entrant in the post-GLP-1 weight maintenance category, addressing what Fractyl estimates is a large and growing unmet need. Most patients who start GLP-1 therapies eventually discontinue them due to cost, side effects or the burden of chronic injections, and weight regain is common after stopping. If approved, Revita could capture a share of that maintenance market, though the pivotal trial data and regulatory pathway remain key milestones. Fractyl shares, trading below $1, have gained roughly 20% on the news but remain well off their 52-week highs as investors await the larger pivotal readout.
This article is for informational purposes only and does not constitute investment advice.
